661 results on '"Salazar, Ramon"'
Search Results
2. Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
3. Random Forest Modeling of Acute Toxicity in Anal Cancer: Effects of Peritoneal Cavity Contouring Approaches on Model Performance
4. MmCMS: mouse models’ consensus molecular subtypes of colorectal cancer
5. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
6. Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer
7. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
8. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
9. Performance comparison of ten state-of-the-art machine learning algorithms for outcome prediction modeling of radiation-induced toxicity
10. Multi-region Multiomic Random Forest Toxicity Modeling of Radiation Pneumonitis.
11. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
12. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
13. Author Correction: COLONOMICS - integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients
14. COLONOMICS - integrative omics data of one hundred paired normal-tumoral samples from colon cancer patients
15. Learning in times of stress: Lessons from COVID-19 that will last throughout this century
16. Analyzing the Relationship between Dose and Geometric Agreement Metrics for Auto-Contouring in Head and Neck Normal Tissues.
17. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
18. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
19. Paradoxical activation of oncogenic signaling as a cancer treatment strategy
20. Long term patient-reported dyspareunia following definitive chemoradiation for anal cancer: utilizing the anterior vaginal wall as an organ-at-risk to define an actionable dosimetric goal
21. Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry
22. Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
23. Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Oncología Médica y de la Sociedad Española de Anatomía Patológica
24. From Fowler-Nordheim to Non-Equilibrium Green's Function Modeling of Tunneling
25. A Predictive Analytic Model for High-Performance Tunneling-Field Effect Transistors Approaching Non-Equilibrium Green's Function Simulations
26. Geo-Solar Geometry: A Teaching Tool for Understanding the Sun Orbits Around Any Point on Earth: A Global Three-Dimensional Solar Chart
27. Medical Oncology Management of Hereditary Colorectal Cancer
28. Photomontage of Images with the Same Point of View
29. Random forest modeling of acute toxicity in anal cancer: Effects of peritoneal cavity contouring approaches on model performance
30. Corrigendum to “Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours” [Eur J Cancer 188 (2023) 39–48]
31. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
32. IKKα kinase coordinates BRD4 and STAT3 signaling to subvert DNA damage-based anticancer therapy
33. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
34. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer center network
35. Supplementary Figure Legends from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
36. Supplementary Table 3 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
37. Supplementary Table S4 from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
38. Supplementary Table 2 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
39. Supplementary Figure 3 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
40. Data from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
41. Supplementary Figure 4 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
42. Table S7 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
43. Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
44. Data from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
45. Supplementary Figure 1 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
46. Data from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
47. Supplementary Table 4 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
48. Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
49. Supplementary Figure 2 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
50. Supplementary Table 1 from A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.